{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T07:44:57Z","timestamp":1724485497843},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1097\/rlu.0000000000001096","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T13:34:30Z","timestamp":1450272870000},"page":"194-200","source":"Crossref","is-referenced-by-count":16,"title":["Comparison of 111In-[DTPA0]Octreotide Versus Non Carrier Added 177Lu- [DOTA0,Tyr3]-Octreotate Efficacy in Patients With GEP-NET Treated Intra-arterially for Liver Metastases"],"prefix":"10.1097","volume":"41","author":[{"given":"G. S.","family":"Limouris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Poulantzas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Trompoukis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Karfis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Chondrogiannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Triantafyllou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Gennimata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.-E.","family":"Moulopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Patsouris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Nikou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Michalaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Fragulidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Paphiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. V.","family":"McCready","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M.","family":"Colletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Rubello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210204","first-page":"2002","article-title":"Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide.","volume":"37","author":"Andersson","year":"1996","journal-title":"J Nucl Med"},{"key":"R2-4-20210204","first-page":"1514","article-title":"Nuclear localization of 111In after intravenous injection of 111In-DTPA-D-Phe1-octreotide in patients with neuroendocrine tumors.","volume":"41","author":"Janson","year":"2000","journal-title":"J Nucl Med"},{"key":"R3-4-20210204","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1007\/s00259-006-0187-2","article-title":"Auger radiation targeted into DNA: a therapy perspective.","volume":"33","author":"Buchegger","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R4-4-20210204","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00259-008-0779-0","article-title":"Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases.","volume":"35","author":"Limouris","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R6-4-20210204","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with In-DTPAoctreotide: the Rotterdam experience.","volume":"32","author":"Valkema","year":"2002","journal-title":"Semin Nucl Med"},{"key":"R7-4-20210204","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00259-002-1050-8","article-title":"Treatment of patients with gastroentero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue 177Lu-DOTA, Tyr3 octreotate.","volume":"30","author":"Kwekkeboom","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R8-4-20210204","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00006231-200001000-00016","article-title":"Toxicity of high-activity 111In-octreotide therapy in patients with disseminated neuroendocrine tumours.","volume":"21","author":"Caplin","year":"2000","journal-title":"Nucl Med Commun"},{"key":"R9-4-20210204","first-page":"551","article-title":"Super-selective hepatic arterial infusions as established technique (ARETAIEION Protocol) of 177LuDOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumours.","volume":"56","author":"Limouris","year":"2012","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R10-4-20210204","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1148\/radiology.181.2.1924786","article-title":"Segmental anatomy of the liver: a sonographic approach to the Couinaud nomenclature.","volume":"181","author":"Lafortune","year":"1991","journal-title":"Radiology"},{"key":"R11-4-20210204","first-page":"37S","article-title":"MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates.","volume":"40","author":"Siegel","year":"1999","journal-title":"J Nucl Med"},{"key":"R12-4-20210204","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2967\/jnumed.108.061150","article-title":"Radiation-induced thyroid stunning: differential effects of (123)I, (131)I, (99m)Tc, and (211)At on iodide transport and NIS mRNA expression in cultured thyroid cells.","volume":"50","author":"Lundh","year":"2009","journal-title":"J Nucl Med"},{"key":"R13-4-20210204","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R14-4-20210204","first-page":"538","article-title":"MIRDOSE: personal computer software for internal dose assessment in nuclear medicine.","volume":"37","author":"Stabin","year":"1996","journal-title":"J Nucl Med"},{"key":"R15-4-20210204","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"R16-4-20210204","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000362558","article-title":"Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.","volume":"99","author":"Kesavan","year":"2014","journal-title":"Neuroendocrinology"},{"key":"R17-4-20210204","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00001622-200201000-00008","article-title":"Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment.","volume":"14","author":"Oberg","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"R18-4-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2265.1999.00756.x","article-title":"Apoptosis in neuroendocrine tumours.","volume":"51","author":"Wang","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R19-4-20210204","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1749-6632.1994.tb17300.x","article-title":"Radiotherapy with a radiolabeled somatostatin analogue, 111In-DTPA-D-Phe1-octreotide. A case history.","volume":"733","author":"Krenning","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"R20-4-20210204","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with 111In-DTPA-D-Phe1- and 123I-Tyr3-octreotide: the Rotterdam experience with more than 1000 patients.","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur J Nucl Med"},{"key":"R21-4-20210204","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/028418699431465","article-title":"Treatment with high dose (111)In-DTPA-D-PHE1-octreotide in patients with neuroendocrine tumors-evaluation of therapeutic and toxic effects.","volume":"38","author":"Tiensuu Janson","year":"1999","journal-title":"Acta Oncol"},{"key":"R22-4-20210204","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00006231-200001000-00016","article-title":"Toxicity of high-activity 111In-Octreotide therapy in patients with disseminated neuroendocrine tumours.","volume":"21","author":"Caplin","year":"2000","journal-title":"Nucl Med Commun"},{"key":"R23-4-20210204","first-page":"1660","article-title":"Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy.","volume":"45","author":"Nguyen","year":"2004","journal-title":"J Nucl Med"},{"key":"R24-4-20210204","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1007\/s00259-012-2210-0","article-title":"Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide.","volume":"39","author":"Boubaker","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R25-4-20210204","first-page":"1","article-title":"Long-term efficacy of high-activity 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumors.","volume":"44","author":"Buscombe","year":"2003","journal-title":"J Nucl Med"},{"key":"R26-4-20210204","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/snuc.2002.31769","article-title":"Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.","volume":"32","author":"Anthony","year":"2002","journal-title":"Semin Nucl Med"},{"key":"R27-4-20210204","doi-asserted-by":"crossref","first-page":"472","DOI":"10.7150\/thno.3739","article-title":"Long-term Survival, toxicity profile, and role of F-18 FDG PETCT scan in patients with progressive neuroendocrine tumors following peptide receptor radionuclide therapy with high activity In-111 pentetreotide.","volume":"2","author":"Delpassand","year":"2012","journal-title":"Theranostics"},{"key":"R28-4-20210204","first-page":"S427","article-title":"Increasing intrahepatic tumour uptake of 111In-DTPA-octreotide by loco regional administration.","volume":"36","author":"Pool","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R29-4-20210204","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-10-0004","article-title":"Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PETCT in patients with gastroenteropancreatic neuroendocrine tumors.","volume":"16","author":"Kratochwil","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R31-4-20210204","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","article-title":"Radiolabeled somatostatin analog 177Lu-DOTA0,Tyr3octreotate in patients with endocrine gastroenteropancreatic tumors.","volume":"23","author":"Kwekkeboom","year":"2005","journal-title":"J Clin Oncol"},{"key":"R32-4-20210204","first-page":"394","article-title":"Targeted radiotherapy of neuroendocrine tumors using Lu-177 DOTA octreotate with prolonged intervals.","volume":"48","author":"Ezziddin","year":"2007","journal-title":"J Nucl Med"},{"key":"R33-4-20210204","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog 177 Lu-DOTA 0,Tyr3octreotate: toxicity, efficacy, and survival.","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"R34-4-20210204","first-page":"92","article-title":"Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients.","volume":"54","author":"Gabriel","year":"2010","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R35-4-20210204","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/cncr.24796","article-title":"177Lu-DOTA0,Tyr3 octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.","volume":"116","author":"Garkavij","year":"2010","journal-title":"Cancer"},{"key":"R36-4-20210204","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2967\/jnumed.109.068957","article-title":"Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors.","volume":"51","author":"van Essen","year":"2010","journal-title":"J Nucl Med"},{"key":"R37-4-20210204","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study.","volume":"38","author":"Bodei","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R38-4-20210204","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00259-010-1631-x","article-title":"Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.","volume":"38","author":"Claringbold","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000001096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:14:17Z","timestamp":1620972857000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201603000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000001096","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}